This research report provides a comprehensive analysis of the Therapeutic Monoclonal Antibodies market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Therapeutic Monoclonal Antibodies market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Therapeutic Monoclonal Antibodies, challenges faced by the industry, and potential opportunities for market players.
The global Therapeutic Monoclonal Antibodies market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Therapeutic Monoclonal Antibodies market presents opportunities for various stakeholders, including Immune Diseases, Cancer. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Therapeutic Monoclonal Antibodies market. Additionally, the growing consumer demand present avenues for market expansion.
The global Therapeutic Monoclonal Antibodies market was valued at US$ 153180 million in 2022 and is projected to reach US$ 325140 million by 2029, at a CAGR of 11.6% during the forecast period.
The Therapeutic Antibodies Drug Market is driven by the remarkable potential of therapeutic antibodies to treat a diverse array of diseases, from cancer and autoimmune disorders to infectious diseases. Monoclonal antibodies have gained prominence as highly targeted and effective therapeutic agents that can modulate the immune system, neutralize pathogens, and inhibit disease-associated proteins. As precision medicine and biopharmaceutical innovations continue to advance, the demand for therapeutic antibodies grows. Innovations in antibody design, engineering, and manufacturing technologies further contribute to market expansion. Nevertheless, a significant challenge for this market is the need to address high production costs, optimize therapeutic antibody development processes, and navigate complex regulatory pathways while ensuring accessibility and affordability for patients. Overcoming manufacturing complexities, managing research and development costs, and addressing regulatory standards are ongoing challenges. Additionally, the market faces competition from small molecules and other biologic therapies, necessitating continuous research and development efforts to unlock the full therapeutic potential of therapeutic antibodies. Striking a balance between providing safe, effective, and accessible therapeutic antibody drugs while addressing scientific and regulatory challenges is essential for the continued growth of the Therapeutic Antibodies Drug Market.
Key Features:
The research report on the Therapeutic Monoclonal Antibodies market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Therapeutic Monoclonal Antibodies market.
Market Overview: The report provides a comprehensive overview of the Therapeutic Monoclonal Antibodies market, including its definition, historical development, and current market size. It covers market segmentation by Type e.g., Mouse-derived Antibodies, Chimeric Antibodies, region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Therapeutic Monoclonal Antibodies market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Therapeutic Monoclonal Antibodies markets trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Therapeutic Monoclonal Antibodies market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Therapeutic Monoclonal Antibodies market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Therapeutic Monoclonal Antibodies market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Therapeutic Monoclonal Antibodies market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Therapeutic Monoclonal Antibodies, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Therapeutic Monoclonal Antibodies market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Therapeutic Monoclonal Antibodies market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Mouse-derived Antibodies
Chimeric Antibodies
Humanized Antibodies
Market segment by Application
Immune Diseases
Cancer
Other
Global Therapeutic Monoclonal Antibodies Market Segment Percentages, By Region and Country, 2022 %
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
AbbVie
Johnson & Johnson
Novartis
Gilead Sciences
Roche
Bristol-Myers Squibb
Amgen
AstraZeneca
Merck & Co
Takeda
Merck KGaA
Seagen
Eli Lilly
Ono Pharmaceutical
Pfizer
Regeneron
Innovent
Hengrui Medicine
Outline of Major Chapters:
Chapter 1: Introduces the definition of Therapeutic Monoclonal Antibodies, market overview.
Chapter 2: Global Therapeutic Monoclonal Antibodies market size in revenue.
Chapter 3: Detailed analysis of Therapeutic Monoclonal Antibodies company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Therapeutic Monoclonal Antibodies in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 Therapeutic Monoclonal Antibodies Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Therapeutic Monoclonal Antibodies Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Therapeutic Monoclonal Antibodies Overall Market Size
2.1 Global Therapeutic Monoclonal Antibodies Market Size: 2022 VS 2029
2.2 Global Therapeutic Monoclonal Antibodies Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Therapeutic Monoclonal Antibodies Players in Global Market
3.2 Top Global Therapeutic Monoclonal Antibodies Companies Ranked by Revenue
3.3 Global Therapeutic Monoclonal Antibodies Revenue by Companies
3.4 Top 3 and Top 5 Therapeutic Monoclonal Antibodies Companies in Global Market, by Revenue in 2022
3.5 Global Companies Therapeutic Monoclonal Antibodies Product Type
3.6 Tier 1, Tier 2 and Tier 3 Therapeutic Monoclonal Antibodies Players in Global Market
3.6.1 List of Global Tier 1 Therapeutic Monoclonal Antibodies Companies
3.6.2 List of Global Tier 2 and Tier 3 Therapeutic Monoclonal Antibodies Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Therapeutic Monoclonal Antibodies Market Size Markets, 2022 & 2029
4.1.2 Mouse-derived Antibodies
4.1.3 Chimeric Antibodies
4.1.4 Humanized Antibodies
4.2 By Type - Global Therapeutic Monoclonal Antibodies Revenue & Forecasts
4.2.1 By Type - Global Therapeutic Monoclonal Antibodies Revenue, 2018-2023
4.2.2 By Type - Global Therapeutic Monoclonal Antibodies Revenue, 2024-2029
4.2.3 By Type - Global Therapeutic Monoclonal Antibodies Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Therapeutic Monoclonal Antibodies Market Size, 2022 & 2029
5.1.2 Immune Diseases
5.1.3 Cancer
5.1.4 Other
5.2 By Application - Global Therapeutic Monoclonal Antibodies Revenue & Forecasts
5.2.1 By Application - Global Therapeutic Monoclonal Antibodies Revenue, 2018-2023
5.2.2 By Application - Global Therapeutic Monoclonal Antibodies Revenue, 2024-2029
5.2.3 By Application - Global Therapeutic Monoclonal Antibodies Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region - Global Therapeutic Monoclonal Antibodies Market Size, 2022 & 2029
6.2 By Region - Global Therapeutic Monoclonal Antibodies Revenue & Forecasts
6.2.1 By Region - Global Therapeutic Monoclonal Antibodies Revenue, 2018-2023
6.2.2 By Region - Global Therapeutic Monoclonal Antibodies Revenue, 2024-2029
6.2.3 By Region - Global Therapeutic Monoclonal Antibodies Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country - North America Therapeutic Monoclonal Antibodies Revenue, 2018-2029
6.3.2 US Therapeutic Monoclonal Antibodies Market Size, 2018-2029
6.3.3 Canada Therapeutic Monoclonal Antibodies Market Size, 2018-2029
6.3.4 Mexico Therapeutic Monoclonal Antibodies Market Size, 2018-2029
6.4 Europe
6.4.1 By Country - Europe Therapeutic Monoclonal Antibodies Revenue, 2018-2029
6.4.2 Germany Therapeutic Monoclonal Antibodies Market Size, 2018-2029
6.4.3 France Therapeutic Monoclonal Antibodies Market Size, 2018-2029
6.4.4 U.K. Therapeutic Monoclonal Antibodies Market Size, 2018-2029
6.4.5 Italy Therapeutic Monoclonal Antibodies Market Size, 2018-2029
6.4.6 Russia Therapeutic Monoclonal Antibodies Market Size, 2018-2029
6.4.7 Nordic Countries Therapeutic Monoclonal Antibodies Market Size, 2018-2029
6.4.8 Benelux Therapeutic Monoclonal Antibodies Market Size, 2018-2029
6.5 Asia
6.5.1 By Region - Asia Therapeutic Monoclonal Antibodies Revenue, 2018-2029
6.5.2 China Therapeutic Monoclonal Antibodies Market Size, 2018-2029
6.5.3 Japan Therapeutic Monoclonal Antibodies Market Size, 2018-2029
6.5.4 South Korea Therapeutic Monoclonal Antibodies Market Size, 2018-2029
6.5.5 Southeast Asia Therapeutic Monoclonal Antibodies Market Size, 2018-2029
6.5.6 India Therapeutic Monoclonal Antibodies Market Size, 2018-2029
6.6 South America
6.6.1 By Country - South America Therapeutic Monoclonal Antibodies Revenue, 2018-2029
6.6.2 Brazil Therapeutic Monoclonal Antibodies Market Size, 2018-2029
6.6.3 Argentina Therapeutic Monoclonal Antibodies Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Therapeutic Monoclonal Antibodies Revenue, 2018-2029
6.7.2 Turkey Therapeutic Monoclonal Antibodies Market Size, 2018-2029
6.7.3 Israel Therapeutic Monoclonal Antibodies Market Size, 2018-2029
6.7.4 Saudi Arabia Therapeutic Monoclonal Antibodies Market Size, 2018-2029
6.7.5 UAE Therapeutic Monoclonal Antibodies Market Size, 2018-2029
7 Therapeutic Monoclonal Antibodies Companies Profiles
7.1 AbbVie
7.1.1 AbbVie Company Summary
7.1.2 AbbVie Business Overview
7.1.3 AbbVie Therapeutic Monoclonal Antibodies Major Product Offerings
7.1.4 AbbVie Therapeutic Monoclonal Antibodies Revenue in Global Market 2018-2023
7.1.5 AbbVie Key News & Latest Developments
7.2 Johnson & Johnson
7.2.1 Johnson & Johnson Company Summary
7.2.2 Johnson & Johnson Business Overview
7.2.3 Johnson & Johnson Therapeutic Monoclonal Antibodies Major Product Offerings
7.2.4 Johnson & Johnson Therapeutic Monoclonal Antibodies Revenue in Global Market 2018-2023
7.2.5 Johnson & Johnson Key News & Latest Developments
7.3 Novartis
7.3.1 Novartis Company Summary
7.3.2 Novartis Business Overview
7.3.3 Novartis Therapeutic Monoclonal Antibodies Major Product Offerings
7.3.4 Novartis Therapeutic Monoclonal Antibodies Revenue in Global Market 2018-2023
7.3.5 Novartis Key News & Latest Developments
7.4 Gilead Sciences
7.4.1 Gilead Sciences Company Summary
7.4.2 Gilead Sciences Business Overview
7.4.3 Gilead Sciences Therapeutic Monoclonal Antibodies Major Product Offerings
7.4.4 Gilead Sciences Therapeutic Monoclonal Antibodies Revenue in Global Market 2018-2023
7.4.5 Gilead Sciences Key News & Latest Developments
7.5 Roche
7.5.1 Roche Company Summary
7.5.2 Roche Business Overview
7.5.3 Roche Therapeutic Monoclonal Antibodies Major Product Offerings
7.5.4 Roche Therapeutic Monoclonal Antibodies Revenue in Global Market 2018-2023
7.5.5 Roche Key News & Latest Developments
7.6 Bristol-Myers Squibb
7.6.1 Bristol-Myers Squibb Company Summary
7.6.2 Bristol-Myers Squibb Business Overview
7.6.3 Bristol-Myers Squibb Therapeutic Monoclonal Antibodies Major Product Offerings
7.6.4 Bristol-Myers Squibb Therapeutic Monoclonal Antibodies Revenue in Global Market 2018-2023
7.6.5 Bristol-Myers Squibb Key News & Latest Developments
7.7 Amgen
7.7.1 Amgen Company Summary
7.7.2 Amgen Business Overview
7.7.3 Amgen Therapeutic Monoclonal Antibodies Major Product Offerings
7.7.4 Amgen Therapeutic Monoclonal Antibodies Revenue in Global Market 2018-2023
7.7.5 Amgen Key News & Latest Developments
7.8 AstraZeneca
7.8.1 AstraZeneca Company Summary
7.8.2 AstraZeneca Business Overview
7.8.3 AstraZeneca Therapeutic Monoclonal Antibodies Major Product Offerings
7.8.4 AstraZeneca Therapeutic Monoclonal Antibodies Revenue in Global Market 2018-2023
7.8.5 AstraZeneca Key News & Latest Developments
7.9 Merck & Co
7.9.1 Merck & Co Company Summary
7.9.2 Merck & Co Business Overview
7.9.3 Merck & Co Therapeutic Monoclonal Antibodies Major Product Offerings
7.9.4 Merck & Co Therapeutic Monoclonal Antibodies Revenue in Global Market 2018-2023
7.9.5 Merck & Co Key News & Latest Developments
7.10 Takeda
7.10.1 Takeda Company Summary
7.10.2 Takeda Business Overview
7.10.3 Takeda Therapeutic Monoclonal Antibodies Major Product Offerings
7.10.4 Takeda Therapeutic Monoclonal Antibodies Revenue in Global Market 2018-2023
7.10.5 Takeda Key News & Latest Developments
7.11 Merck KGaA
7.11.1 Merck KGaA Company Summary
7.11.2 Merck KGaA Business Overview
7.11.3 Merck KGaA Therapeutic Monoclonal Antibodies Major Product Offerings
7.11.4 Merck KGaA Therapeutic Monoclonal Antibodies Revenue in Global Market 2018-2023
7.11.5 Merck KGaA Key News & Latest Developments
7.12 Seagen
7.12.1 Seagen Company Summary
7.12.2 Seagen Business Overview
7.12.3 Seagen Therapeutic Monoclonal Antibodies Major Product Offerings
7.12.4 Seagen Therapeutic Monoclonal Antibodies Revenue in Global Market 2018-2023
7.12.5 Seagen Key News & Latest Developments
7.13 Eli Lilly
7.13.1 Eli Lilly Company Summary
7.13.2 Eli Lilly Business Overview
7.13.3 Eli Lilly Therapeutic Monoclonal Antibodies Major Product Offerings
7.13.4 Eli Lilly Therapeutic Monoclonal Antibodies Revenue in Global Market 2018-2023
7.13.5 Eli Lilly Key News & Latest Developments
7.14 Ono Pharmaceutical
7.14.1 Ono Pharmaceutical Company Summary
7.14.2 Ono Pharmaceutical Business Overview
7.14.3 Ono Pharmaceutical Therapeutic Monoclonal Antibodies Major Product Offerings
7.14.4 Ono Pharmaceutical Therapeutic Monoclonal Antibodies Revenue in Global Market 2018-2023
7.14.5 Ono Pharmaceutical Key News & Latest Developments
7.15 Pfizer
7.15.1 Pfizer Company Summary
7.15.2 Pfizer Business Overview
7.15.3 Pfizer Therapeutic Monoclonal Antibodies Major Product Offerings
7.15.4 Pfizer Therapeutic Monoclonal Antibodies Revenue in Global Market 2018-2023
7.15.5 Pfizer Key News & Latest Developments
7.16 Regeneron
7.16.1 Regeneron Company Summary
7.16.2 Regeneron Business Overview
7.16.3 Regeneron Therapeutic Monoclonal Antibodies Major Product Offerings
7.16.4 Regeneron Therapeutic Monoclonal Antibodies Revenue in Global Market 2018-2023
7.16.5 Regeneron Key News & Latest Developments
7.17 Innovent
7.17.1 Innovent Company Summary
7.17.2 Innovent Business Overview
7.17.3 Innovent Therapeutic Monoclonal Antibodies Major Product Offerings
7.17.4 Innovent Therapeutic Monoclonal Antibodies Revenue in Global Market 2018-2023
7.17.5 Innovent Key News & Latest Developments
7.18 Hengrui Medicine
7.18.1 Hengrui Medicine Company Summary
7.18.2 Hengrui Medicine Business Overview
7.18.3 Hengrui Medicine Therapeutic Monoclonal Antibodies Major Product Offerings
7.18.4 Hengrui Medicine Therapeutic Monoclonal Antibodies Revenue in Global Market 2018-2023
7.18.5 Hengrui Medicine Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
List of Tables
Table 1. Therapeutic Monoclonal Antibodies Market Opportunities & Trends in Global Market
Table 2. Therapeutic Monoclonal Antibodies Market Drivers in Global Market
Table 3. Therapeutic Monoclonal Antibodies Market Restraints in Global Market
Table 4. Key Players of Therapeutic Monoclonal Antibodies in Global Market
Table 5. Top Therapeutic Monoclonal Antibodies Players in Global Market, Ranking by Revenue 2022
Table 6. Global Therapeutic Monoclonal Antibodies Revenue by Companies, US$, Mn, 2018-2023
Table 7. Global Therapeutic Monoclonal Antibodies Revenue Share by Companies, 2018-2023
Table 8. Global Companies Therapeutic Monoclonal Antibodies Product Type
Table 9. List of Global Tier 1 Therapeutic Monoclonal Antibodies Companies, Revenue US$, Mn in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Therapeutic Monoclonal Antibodies Companies, Revenue US$, Mn in 2022 and Market Share
Table 11. By Type – Global Therapeutic Monoclonal Antibodies Revenue, US$, Mn, 2022 & 2029
Table 12. By Type - Therapeutic Monoclonal Antibodies Revenue in Global US$, Mn, 2018-2023
Table 13. By Type - Therapeutic Monoclonal Antibodies Revenue in Global US$, Mn, 2024-2029
Table 14. By Application – Global Therapeutic Monoclonal Antibodies Revenue, US$, Mn, 2022 & 2029
Table 15. By Application - Therapeutic Monoclonal Antibodies Revenue in Global US$, Mn, 2018-2023
Table 16. By Application - Therapeutic Monoclonal Antibodies Revenue in Global US$, Mn, 2024-2029
Table 17. By Region – Global Therapeutic Monoclonal Antibodies Revenue, US$, Mn, 2022 & 2029
Table 18. By Region - Global Therapeutic Monoclonal Antibodies Revenue US$, Mn, 2018-2023
Table 19. By Region - Global Therapeutic Monoclonal Antibodies Revenue US$, Mn, 2024-2029
Table 20. By Country - North America Therapeutic Monoclonal Antibodies Revenue, US$, Mn, 2018-2023
Table 21. By Country - North America Therapeutic Monoclonal Antibodies Revenue, US$, Mn, 2024-2029
Table 22. By Country - Europe Therapeutic Monoclonal Antibodies Revenue, US$, Mn, 2018-2023
Table 23. By Country - Europe Therapeutic Monoclonal Antibodies Revenue, US$, Mn, 2024-2029
Table 24. By Region - Asia Therapeutic Monoclonal Antibodies Revenue, US$, Mn, 2018-2023
Table 25. By Region - Asia Therapeutic Monoclonal Antibodies Revenue, US$, Mn, 2024-2029
Table 26. By Country - South America Therapeutic Monoclonal Antibodies Revenue, US$, Mn, 2018-2023
Table 27. By Country - South America Therapeutic Monoclonal Antibodies Revenue, US$, Mn, 2024-2029
Table 28. By Country - Middle East & Africa Therapeutic Monoclonal Antibodies Revenue, US$, Mn, 2018-2023
Table 29. By Country - Middle East & Africa Therapeutic Monoclonal Antibodies Revenue, US$, Mn, 2024-2029
Table 30. AbbVie Company Summary
Table 31. AbbVie Therapeutic Monoclonal Antibodies Product Offerings
Table 32. AbbVie Therapeutic Monoclonal Antibodies Revenue US$, Mn & 2018-2023
Table 33. AbbVie Key News & Latest Developments
Table 34. Johnson & Johnson Company Summary
Table 35. Johnson & Johnson Therapeutic Monoclonal Antibodies Product Offerings
Table 36. Johnson & Johnson Therapeutic Monoclonal Antibodies Revenue US$, Mn & 2018-2023
Table 37. Johnson & Johnson Key News & Latest Developments
Table 38. Novartis Company Summary
Table 39. Novartis Therapeutic Monoclonal Antibodies Product Offerings
Table 40. Novartis Therapeutic Monoclonal Antibodies Revenue US$, Mn & 2018-2023
Table 41. Novartis Key News & Latest Developments
Table 42. Gilead Sciences Company Summary
Table 43. Gilead Sciences Therapeutic Monoclonal Antibodies Product Offerings
Table 44. Gilead Sciences Therapeutic Monoclonal Antibodies Revenue US$, Mn & 2018-2023
Table 45. Gilead Sciences Key News & Latest Developments
Table 46. Roche Company Summary
Table 47. Roche Therapeutic Monoclonal Antibodies Product Offerings
Table 48. Roche Therapeutic Monoclonal Antibodies Revenue US$, Mn & 2018-2023
Table 49. Roche Key News & Latest Developments
Table 50. Bristol-Myers Squibb Company Summary
Table 51. Bristol-Myers Squibb Therapeutic Monoclonal Antibodies Product Offerings
Table 52. Bristol-Myers Squibb Therapeutic Monoclonal Antibodies Revenue US$, Mn & 2018-2023
Table 53. Bristol-Myers Squibb Key News & Latest Developments
Table 54. Amgen Company Summary
Table 55. Amgen Therapeutic Monoclonal Antibodies Product Offerings
Table 56. Amgen Therapeutic Monoclonal Antibodies Revenue US$, Mn & 2018-2023
Table 57. Amgen Key News & Latest Developments
Table 58. AstraZeneca Company Summary
Table 59. AstraZeneca Therapeutic Monoclonal Antibodies Product Offerings
Table 60. AstraZeneca Therapeutic Monoclonal Antibodies Revenue US$, Mn & 2018-2023
Table 61. AstraZeneca Key News & Latest Developments
Table 62. Merck & Co Company Summary
Table 63. Merck & Co Therapeutic Monoclonal Antibodies Product Offerings
Table 64. Merck & Co Therapeutic Monoclonal Antibodies Revenue US$, Mn & 2018-2023
Table 65. Merck & Co Key News & Latest Developments
Table 66. Takeda Company Summary
Table 67. Takeda Therapeutic Monoclonal Antibodies Product Offerings
Table 68. Takeda Therapeutic Monoclonal Antibodies Revenue US$, Mn & 2018-2023
Table 69. Takeda Key News & Latest Developments
Table 70. Merck KGaA Company Summary
Table 71. Merck KGaA Therapeutic Monoclonal Antibodies Product Offerings
Table 72. Merck KGaA Therapeutic Monoclonal Antibodies Revenue US$, Mn & 2018-2023
Table 73. Merck KGaA Key News & Latest Developments
Table 74. Seagen Company Summary
Table 75. Seagen Therapeutic Monoclonal Antibodies Product Offerings
Table 76. Seagen Therapeutic Monoclonal Antibodies Revenue US$, Mn & 2018-2023
Table 77. Seagen Key News & Latest Developments
Table 78. Eli Lilly Company Summary
Table 79. Eli Lilly Therapeutic Monoclonal Antibodies Product Offerings
Table 80. Eli Lilly Therapeutic Monoclonal Antibodies Revenue US$, Mn & 2018-2023
Table 81. Eli Lilly Key News & Latest Developments
Table 82. Ono Pharmaceutical Company Summary
Table 83. Ono Pharmaceutical Therapeutic Monoclonal Antibodies Product Offerings
Table 84. Ono Pharmaceutical Therapeutic Monoclonal Antibodies Revenue US$, Mn & 2018-2023
Table 85. Ono Pharmaceutical Key News & Latest Developments
Table 86. Pfizer Company Summary
Table 87. Pfizer Therapeutic Monoclonal Antibodies Product Offerings
Table 88. Pfizer Therapeutic Monoclonal Antibodies Revenue US$, Mn & 2018-2023
Table 89. Pfizer Key News & Latest Developments
Table 90. Regeneron Company Summary
Table 91. Regeneron Therapeutic Monoclonal Antibodies Product Offerings
Table 92. Regeneron Therapeutic Monoclonal Antibodies Revenue US$, Mn & 2018-2023
Table 93. Regeneron Key News & Latest Developments
Table 94. Innovent Company Summary
Table 95. Innovent Therapeutic Monoclonal Antibodies Product Offerings
Table 96. Innovent Therapeutic Monoclonal Antibodies Revenue US$, Mn & 2018-2023
Table 97. Innovent Key News & Latest Developments
Table 98. Hengrui Medicine Company Summary
Table 99. Hengrui Medicine Therapeutic Monoclonal Antibodies Product Offerings
Table 100. Hengrui Medicine Therapeutic Monoclonal Antibodies Revenue US$, Mn & 2018-2023
Table 101. Hengrui Medicine Key News & Latest Developments
List of Figures
Figure 1. Therapeutic Monoclonal Antibodies Segment by Type in 2022
Figure 2. Therapeutic Monoclonal Antibodies Segment by Application in 2022
Figure 3. Global Therapeutic Monoclonal Antibodies Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Therapeutic Monoclonal Antibodies Market Size: 2022 VS 2029 US$, Mn
Figure 6. Global Therapeutic Monoclonal Antibodies Revenue, 2018-2029 US$, Mn
Figure 7. The Top 3 and 5 Players Market Share by Therapeutic Monoclonal Antibodies Revenue in 2022
Figure 8. By Type - Global Therapeutic Monoclonal Antibodies Revenue Market Share, 2018-2029
Figure 9. By Application - Global Therapeutic Monoclonal Antibodies Revenue Market Share, 2018-2029
Figure 10. By Type - Global Therapeutic Monoclonal Antibodies Revenue, US$, Mn, 2022 & 2029
Figure 11. By Type - Global Therapeutic Monoclonal Antibodies Revenue Market Share, 2018-2029
Figure 12. By Application - Global Therapeutic Monoclonal Antibodies Revenue, US$, Mn, 2022 & 2029
Figure 13. By Application - Global Therapeutic Monoclonal Antibodies Revenue Market Share, 2018-2029
Figure 14. By Region - Global Therapeutic Monoclonal Antibodies Revenue Market Share, 2018-2029
Figure 15. By Country - North America Therapeutic Monoclonal Antibodies Revenue Market Share, 2018-2029
Figure 16. US Therapeutic Monoclonal Antibodies Revenue, US$, Mn, 2018-2029
Figure 17. Canada Therapeutic Monoclonal Antibodies Revenue, US$, Mn, 2018-2029
Figure 18. Mexico Therapeutic Monoclonal Antibodies Revenue, US$, Mn, 2018-2029
Figure 19. By Country - Europe Therapeutic Monoclonal Antibodies Revenue Market Share, 2018-2029
Figure 20. Germany Therapeutic Monoclonal Antibodies Revenue, US$, Mn, 2018-2029
Figure 21. France Therapeutic Monoclonal Antibodies Revenue, US$, Mn, 2018-2029
Figure 22. U.K. Therapeutic Monoclonal Antibodies Revenue, US$, Mn, 2018-2029
Figure 23. Italy Therapeutic Monoclonal Antibodies Revenue, US$, Mn, 2018-2029
Figure 24. Russia Therapeutic Monoclonal Antibodies Revenue, US$, Mn, 2018-2029
Figure 25. Nordic Countries Therapeutic Monoclonal Antibodies Revenue, US$, Mn, 2018-2029
Figure 26. Benelux Therapeutic Monoclonal Antibodies Revenue, US$, Mn, 2018-2029
Figure 27. By Region - Asia Therapeutic Monoclonal Antibodies Revenue Market Share, 2018-2029
Figure 28. China Therapeutic Monoclonal Antibodies Revenue, US$, Mn, 2018-2029
Figure 29. Japan Therapeutic Monoclonal Antibodies Revenue, US$, Mn, 2018-2029
Figure 30. South Korea Therapeutic Monoclonal Antibodies Revenue, US$, Mn, 2018-2029
Figure 31. Southeast Asia Therapeutic Monoclonal Antibodies Revenue, US$, Mn, 2018-2029
Figure 32. India Therapeutic Monoclonal Antibodies Revenue, US$, Mn, 2018-2029
Figure 33. By Country - South America Therapeutic Monoclonal Antibodies Revenue Market Share, 2018-2029
Figure 34. Brazil Therapeutic Monoclonal Antibodies Revenue, US$, Mn, 2018-2029
Figure 35. Argentina Therapeutic Monoclonal Antibodies Revenue, US$, Mn, 2018-2029
Figure 36. By Country - Middle East & Africa Therapeutic Monoclonal Antibodies Revenue Market Share, 2018-2029
Figure 37. Turkey Therapeutic Monoclonal Antibodies Revenue, US$, Mn, 2018-2029
Figure 38. Israel Therapeutic Monoclonal Antibodies Revenue, US$, Mn, 2018-2029
Figure 39. Saudi Arabia Therapeutic Monoclonal Antibodies Revenue, US$, Mn, 2018-2029
Figure 40. UAE Therapeutic Monoclonal Antibodies Revenue, US$, Mn, 2018-2029
Figure 41. AbbVie Therapeutic Monoclonal Antibodies Revenue Year Over Year Growth US$, Mn & 2018-2023
Figure 42. Johnson & Johnson Therapeutic Monoclonal Antibodies Revenue Year Over Year Growth US$, Mn & 2018-2023
Figure 43. Novartis Therapeutic Monoclonal Antibodies Revenue Year Over Year Growth US$, Mn & 2018-2023
Figure 44. Gilead Sciences Therapeutic Monoclonal Antibodies Revenue Year Over Year Growth US$, Mn & 2018-2023
Figure 45. Roche Therapeutic Monoclonal Antibodies Revenue Year Over Year Growth US$, Mn & 2018-2023
Figure 46. Bristol-Myers Squibb Therapeutic Monoclonal Antibodies Revenue Year Over Year Growth US$, Mn & 2018-2023
Figure 47. Amgen Therapeutic Monoclonal Antibodies Revenue Year Over Year Growth US$, Mn & 2018-2023
Figure 48. AstraZeneca Therapeutic Monoclonal Antibodies Revenue Year Over Year Growth US$, Mn & 2018-2023
Figure 49. Merck & Co Therapeutic Monoclonal Antibodies Revenue Year Over Year Growth US$, Mn & 2018-2023
Figure 50. Takeda Therapeutic Monoclonal Antibodies Revenue Year Over Year Growth US$, Mn & 2018-2023
Figure 51. Merck KGaA Therapeutic Monoclonal Antibodies Revenue Year Over Year Growth US$, Mn & 2018-2023
Figure 52. Seagen Therapeutic Monoclonal Antibodies Revenue Year Over Year Growth US$, Mn & 2018-2023
Figure 53. Eli Lilly Therapeutic Monoclonal Antibodies Revenue Year Over Year Growth US$, Mn & 2018-2023
Figure 54. Ono Pharmaceutical Therapeutic Monoclonal Antibodies Revenue Year Over Year Growth US$, Mn & 2018-2023
Figure 55. Pfizer Therapeutic Monoclonal Antibodies Revenue Year Over Year Growth US$, Mn & 2018-2023
Figure 56. Regeneron Therapeutic Monoclonal Antibodies Revenue Year Over Year Growth US$, Mn & 2018-2023
Figure 57. Innovent Therapeutic Monoclonal Antibodies Revenue Year Over Year Growth US$, Mn & 2018-2023
Figure 58. Hengrui Medicine Therapeutic Monoclonal Antibodies Revenue Year Over Year Growth US$, Mn & 2018-2023
